The experience of use of genetic engineering biological agents in children with juvenile chronic artritis in Buryatia
Автор: Zhdanova Larisa Vladimirovna, Bimbaev Ayur Bato-Zhargalovich
Журнал: Вестник Бурятского государственного университета @vestnik-bsu
Статья в выпуске: 12, 2013 года.
Бесплатный доступ
The article describes the results of the use of infliximab (trade mark Remicaid) - genetic engineering biological agents, in children in the Republic of Buryatia.
Juvenile chronic arthritis, genetic engineering biological agents, infliximab
Короткий адрес: https://sciup.org/148181628
IDR: 148181628
Статья научная
